RxDoctor Payments Data

Lori Leipheimer

Psychiatric/Mental Health · Boardman, OHNPI 1013990845

Payments from drug & device makers

$5,437in general payments, 2019–2025

Across 237 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • AbbVie$956
  • Otsuka America Pharmaceutical, Inc.$724
  • Axsome Therapeutics, Inc.$717
  • Johnson & Johnson$673
  • Vanda Pharmaceuticals Inc.$479
  • plus $700 from 11 others

What the payments were for

  • Food & beverage$5,33198%
  • Education$1062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,437 in reported general payments places this provider in the 90th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$20,535
Medicare patients
23
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SuboxoneBuprenorphine Hcl/Naloxone Hcl28$8,051
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl51$5,187
Aripiprazole81$3,340
Olanzapine29$1,067
Duloxetine Hcl82$1,001
Bupropion XlBupropion Hcl52$945
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$845
Divalproex Sodium ErDivalproex Sodium21$813
Mirtazapine71$747
Trazodone Hcl100$733
Oxcarbazepine14$620
Alprazolam52$495
Venlafaxine Hcl ErVenlafaxine Hcl62$489
Buspirone Hcl26$450
Hydroxyzine Pamoate19$401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$140$8,05128 claims
Almatica Pharma LLCSertraline Hcl$13$13845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Boardman

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →